A Randomized, Double-Blind 4-Week Study to Evaluate the Impact of AXS-05 on Smoking Behavior

Trial Profile

A Randomized, Double-Blind 4-Week Study to Evaluate the Impact of AXS-05 on Smoking Behavior

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Bupropion/dextromethorphan (Primary) ; Bupropion
  • Indications Smoking withdrawal
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Mar 2018 According to an Axsome Therapeutics media release, initiation of this trial is anticipated in the first half of 2018.
    • 23 Feb 2018 Status changed from planning to not yet recruiting.
    • 21 Dec 2017 According to a Axsome Therapeutics media release, James M. Davis is the principal investigator for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top